UBS Group’s CytRx Corp CYTR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q2 | – | Sell |
-2,389
| Closed | -$2K | – | 8518 |
|
|
2019
Q1 | $2K | Buy |
2,389
+1,667
| +231% | +$1.05K | ﹤0.01% | 7506 |
|
|
2018
Q4 | $0 | Sell |
722
-7,858
| -92% | -$5.42K | ﹤0.01% | 8711 |
|
|
2018
Q3 | $9K | Buy |
8,580
+8,078
| +1,609% | +$9.12K | ﹤0.01% | 7249 |
|
|
2018
Q2 | $1K | Hold |
502
| – | – | ﹤0.01% | 7920 |
|
|
2018
Q1 | $1K | Sell |
502
-7,280
| -94% | -$12.8K | ﹤0.01% | 7740 |
|
|
2017
Q4 | $13K | Buy |
7,782
+5,149
| +196% | +$10.7K | ﹤0.01% | 6898 |
|
|
2017
Q3 | $6K | Buy |
2,633
+1,122
| +74% | +$3.79K | ﹤0.01% | 7191 |
|
|
2017
Q2 | $6K | Sell |
1,511
-441
| -23% | -$1.51K | ﹤0.01% | 7089 |
|
|
2017
Q1 | $5K | Sell |
1,952
-7,208
| -79% | -$18.3K | ﹤0.01% | 7041 |
|
|
2016
Q4 | $21K | Buy |
9,160
+9,094
| +13,779% | +$26.7K | ﹤0.01% | 6501 |
|
|
2016
Q3 | $0 | Sell |
66
-2,481
| -97% | -$11.4K | ﹤0.01% | 8362 |
|
|
2016
Q2 | $34K | Buy |
2,547
+2,481
| +3,759% | +$41.3K | ﹤0.01% | 5853 |
|
|
2016
Q1 | $1K | Sell |
66
-211
| -76% | -$2.88K | ﹤0.01% | 7547 |
|
|
2015
Q4 | $4K | Sell |
277
-229
| -45% | -$3.93K | ﹤0.01% | 7841 |
|
|
2015
Q3 | $7K | Sell |
506
-213
| -30% | -$3.61K | ﹤0.01% | 7559 |
|
|
2015
Q2 | $16K | Sell |
719
-155
| -18% | -$3.88K | ﹤0.01% | 7115 |
|
|
2015
Q1 | $17K | Sell |
874
-170
| -16% | -$3.16K | ﹤0.01% | 7185 |
|
|
2014
Q4 | $17K | Buy |
+1,044
| New | +$16.3K | ﹤0.01% | 7932 |
|
Other funds holding CYTR
UBS Group's CYTR Position: Q2 2019 in Review
UBS Group sold out of CytRx Corp (CYTR) in Q2 2019, closing a stake of 2,389 shares — an estimated $2K sold.
UBS Group first reported a position in CYTR in Q4 2014 and held it in 18 quarters. The position peaked at $34K in Q2 2016. 5 funds tracked by Wall St. Rank hold CYTR as of Q2 2019.
- UBS Group reported no remaining CytRx Corp position as of Q2 2019 after selling out during the quarter.
- UBS Group sold 2,389 CytRx Corp shares in Q2 2019, an estimated $2K.
- UBS Group first reported a position in CytRx Corp in Q4 2014 and held it in 18 quarters.
- UBS Group's CytRx Corp position peaked at $34K in Q2 2016.
- 5 funds tracked by Wall St. Rank held CytRx Corp as of Q2 2019.
Based on UBS Group's 13F filing for Q2 2019, filed 14 Aug 2019.